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OBJECTIVES: Define the treatment patterns and associated costs to treat meta-
static prostate cancer in Brazilian private health care system. METHODS: In a na-
tionwide oncology claims database of 3.5 million lives, from August 2010 to July
2011, 67 patients were identifiedwithmetastatic prostate cancer using chemother-
apy. Patients using hormone therapy were excluded. The database gathered infor-
mation regarding the treatment patients were submitted, to average duration and
medication dosage. RESULTS: Patients were on average 71 years old, weighted 78
kilograms and measured 1.70 meters. Among the 67 patients, only 5 (7%) were
submitted to first line treatment with mitoxantrone and 62 (93%) with docetaxel;
58% of all patients took a second line treatment. From the 62 patients that started
with docetaxel (121.5 mg average dose for each of the 6.5 cycles (21days)), 28 had a
second line treatment with mitoxantrone (20mg average dose for each of the 3.9
cycles (21days)) with total average cost/patient of R$ 39,698 (USD 22,056); 7 were
retreated with docetaxel (60mg average dose for each of the 6 cycles (7days)). From
the 5 patients that started with mitoxantrone (20.6mg average dose for each of the
3.2 cycles (21 days)), 4 continued the treatment with docetaxel (60mg average dose
for each of the 3 applications (21 days)) with a total average cost/patient of R$ 12,795
(USD 7,107). CONCLUSIONS: The database suggests that docetaxel is the most
commonly used first line treatment to metastatic prostate cancer in the Brazilian
private health care system. Forty-two percent of the patientswere not submitted to
a second pattern in the period studied, being that 18% of the ones that had a second
line treatment were retreated with the same medication (docetaxel).
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OBJECTIVES: Treatment of bonemetastases secondary to prostate cancer typically
involves different provider types and a combination of surgery, radiation, and
pharmaceutical treatment. This study evaluated treatment patterns and costs for
patients with bone metastases secondary to prostate cancer. Which providers had
patientswith bonemetts that increased costs in surgery, radiation and chemother-
apy compared to no bonemetts?METHODS: Continuously enrolled patients in the
MarketScan database between January 2004 and December 2010 with evidence of
bone metastases (ICD9 code 198.5 or treatment with one of the following medica-
tions: zolderonic acid, pamidronate, or demosumab) were included. The relation-
ship between patterns of care regarding physician specialty, type of therapy and
cost of treatment were assessed. RESULTS: Total of 4493 patients had evidence of
bone metastases. Most patients (n2633, 59%) had both an urologist and a radiol-
ogist involved in their care. Common combinations of providers were urologist and
radiologist (U&R, 22%); urologist, radiologist, and surgeon (U, R&S, 21%), and urol-
ogist, radiologist, and oncologist (U, R&O, 17%). A majority of patient were pre-
scribed hormone therapy (89%) and 76% were prescribed steroid agents (mostly
glucocorticoids). Half of the population received radiation therapy (n2274, 51%)
and 1,838 (41%) received surgery related to their prostate cancer. Significant differ-
ences in total cost, depending on the mix of specialists involved in care: U&R:
$22,133; U, R&S: $28,305; and U, R&O: $34,366 (p0.001 for all pairwise compari-
sons). Common treatment combinations were also associated with significantly
different total costs: patients receiving steroids, radiation, chemotherapy, and hor-
mone treatment cost the most (mean: $47,914) while patients steroids, surgery,
chemotherapy, and hormone therapy cost the least (mean: $31,612).
CONCLUSIONS: Significant variation in patterns of care and total costs for patients
whohave bonemetastases secondary to prostate cancer. Additional studies should
examine the potential drivers of this variation and strategies to maximize cost-
effectiveness.
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OBJECTIVES: Previous studies documenting the clinical and economic burden of
prostate cancer (PCa) have highlighted that a substantial proportion of PCa care is
completed in the inpatient hospital setting. No studies to date, however, have
documented specific patterns of care within the inpatient setting. This study eval-
uated treatments and the associated cost of care for PCa patients treated in an
inpatient setting. METHODS: Patients in the Premier Hospital Database between
January 2006 andDecember 2010 treated in an inpatient setting for PCa (ICD9Codes
185 and 233.4) were included. Patients were required to be40 years of age with no
additional cancers. Utilization of PCa-specific treatments and costs across relevant
inpatient cost centers were assessed and described. RESULTS: There were 88,151
hospitalizations ofmen treated for PCa in an inpatient setting. Themean age of the
sample was 69 years, with 68% being Caucasian. The average hospitalization cost
was $12,286 for 4 days of stay. The most common treatments provided were sur-
gery (57%), miscellaneous drug therapy (39%), hormone therapy (30%), and radia-
tion treatment (4%). Accordingly, approximately 26% of costs were associated with
surgery, and 31% were associated with room and board; pharmaceuticals ac-
counted for 8% of costs. CONCLUSIONS:Men treated for PCa in an inpatient setting
averaged $4516 per day for approximately 4 days, with surgery and miscellaneous
drug therapy being the most frequently used inpatient treatments.
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OBJECTIVES: This study examined total health care expenditures in newly diag-
nosed subjects with colorectal cancer (CRC) over time and by lines of therapy
received.METHODS: Patients aged 18-years and older when newly diagnosed with
CRC between January 1, 2005 and June 31, 2009 were identified using a large, US-
based administrative medical claims (MarketScan) database. Patients were identi-
fied with CRC if they had an ICD-9-CM claim for a primary diagnosis of colon or
rectal cancer on 2 different days but within 180 days of each other. At least 6
months of patient history prior to CRC diagnosis and at least 1-year post-index
continuous enrollment was required. Patients were followed from initial CRC di-
agnosis (index date) to disenrollment or June 31, 2010. Chemotherapy and biologic
treatments over time were analyzed to identify lines of therapy. Total health care
costs included costs associatedwith CRC and other comorbidities. Univariate anal-
yses were performed to examine changes in costs over time and with increasing
lines of therapy. RESULTS:A total of 23,547 subjectswere includedwith amean age
of 65.3 years, 49% were over 65 years, and 52% were males. They were predomi-
nately from the South (40%) and the Midwest region (36%) andmajority (54%) were
enrolled in a preferred provider organization plan. 63% of the subjects received no
systemic treatment for CRC and 17%, 13%, and 7% received 1st line only, 2nd line
only and 3rd lines of treatment for CRC, respectively. Themean annualized costs
increased from $20,785 to $50,255 for those diagnosed in 2005 to 2009 (p-value 
0.001). Themean annualized costs for those receiving 1st line only, 2nd line only and
3rd  lines of treatment were $46,277, $69,244, and $108,819, respectively.
CONCLUSIONS: Annualized total health care costs in newly diagnosed CRC sub-
jects more than doubled from 2005 to 2009 growing faster than medical inflation.
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OBJECTIVES: Prostate cancer is the most frequent non skin cancer in men in west
European countries. The first line treatment in metastatic prostate cancer is hor-
monal therapy, however in 18-24 months it slowly turns over into metastatic hor-
mone resistant prostate cancer (mHRPC). The aim of this analysis was to charac-
terize the economic value of cabazitaxel in second line treatment of mHRPC.
METHODS: A benchmarking analysis was performed, comparing cabazitaxel with
other chemotherapeutic regimes used in second line treatment in Europe. As com-
parators we used drugs registered between 1.1.2004–18.1.2011 by EMA (according
European public assessment report EPAR) for second line treatment of oncologic
diseases. Generic products (as for example docetaxel, topotekan, talidomid, tem-
ezolomid) were not taken into account. As outcome data we used the information
about overall survival from the last analysis, if it was possible intention to treatwas
used. These data was gathered from EPAR and Summary product characteristic
and given into context with market prices, what allowed direct analysis of costs
and outcomes. The total costs for therapy were counted according the median of
therapy duration, dosing and price per milligram. As example we used prices in
Spain. RESULTS: Together 25 substances were detected, in between them orphan
medical products as well. Cabazitaxel demonstrated the second best benefit in
overall survival (cetuximab over the best supportive care HR0.51 [0.41- 0.75,
p0.0001, cabazitaxel over mitoxantrone HR 0.7 [0.59-0.83] p0.0001). According
the price cabazitaxel reached the sixth rank. The price for one vial was 3833 euro
and the price for one patient was 22 998 euro. CONCLUSIONS: The price versus
overall survival hazard ratio comparison detected cabazitaxel as the second sub-
stance, mostly reducing risk of death and thus with costs which are comparable
with other second line treatments in oncology.
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OBJECTIVES: The ENESTnd study showed that in newly-diagnosed patients with
PhCML-CP nilotinib (300mg BID) had greater efficacy than imatinib (400mgQD) in
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the number of patients achieving major molecular and complete cytogenetic re-
sponses. Fewer patients treatedwith nilotinib progressed to advance or blast phase
than with imatinib. The objective of this analysis was to assess, from a HK societal
perspective, the cost and quality-adjusted-life-years (QALYs) of imatinib versus
nilotinib in newly-diagnosed Ph CML-CP. METHODS: A literature-based Markov
model was developed to estimate the lifetime QALYs and costs of typical 47 year-
old CML-CP patients initiating first-line (FL) therapy. Two periods were considered:
the first year, reflecting the ENESTnd data, and all subsequent years (until all pa-
tients had died/reached 100 years), based on stratified disease progression data
from the International Randomized Study of Interferon and STI571 (IRIS) study.
Patients who discontinued FL therapy were modeled to receive one additional
tyrosine kinase inhibitor (TKI). Prognosis after FL therapy discontinuation was
modeled using published studies. Local demographics and costs were used to pop-
ulate themodel. Quality of lifewas assumed to vary by disease stage and treatment
status (on/off TKI). The threshold used to define a cost-effective therapy was the
WHO’s 3 x GDP/capita (i.e., HKD247,712; USD31,758; USD1  HKD7.8). RESULTS:
Compared to imatinib, nilotinib results in a gain of 2.32 life years and 2.30 QALYs.
The cost/life year gain was HKD156,042 (USD20,005) and incremental cost/ QALY
was HKD157,313 (USD20,168). Univariate sensitivity analysis showed results were
generally robust. Key drivers were the duration of analysis, discount rates, age at
therapy initiation, and inclusion/exclusion of indirect costs. In probabilistic sensi-
tivity analysis, 95% of model replications cost HKD 180,000 (USD23,077)/QALY
gained. CONCLUSIONS: Using local and non-local data, this analysis suggests that
nilotinib is cost-effective compared to imatinib as FL treatment for CML-CP pa-
tients from a HK societal perspective.
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OBJECTIVES: Guidelines preferred (category 1) salvage therapies for relapsed/re-
fractory multiple myeloma typically include bortezomib (BTZ) and lenalidomide.
Since no randomized controlled trials (RCT) or relative effectiveness assessments
comparing both drugs exist a comprehensive assessment of the cost-effectiveness
of lenalidomidedexamethasone (LEN/DEX) was performed in different drug se-
quencing (1 prior vs. 1 prior therapy) using indirect comparison. METHODS: A
Markov-type model was designed to assess long-term cost-effectiveness of LEN/
DEX vs BTZ (indirect), using patient-level data from the MM-009/MM-010 RCTs
(LEN/DEX vs. DEX) and published APEX trial data (BTZ vs. DEX). Due to potential
crossover-induced bias, overall survival (OS) was estimated using a quantitative
relationship between time-to-progression/progression-free-survival and OS (cen-
sored normal weighted Tobit regression model, based on 153 studies containing
230 treatment arms and 22,696 MM patients). The indirect comparison was based
on a mixed treatment comparison of time-to-progression from the aforemen-
tioned trials. The Portuguese societal perspective was assumed. Effectiveness was
measured in life years (LY) and quality-adjusted life years (QALY). Annual discount
rates were set at 5%. Probabilistic sensitivity analysis was conducted with Monte-
Carlo simulations. RESULTS: LEN/DEX is estimated to add substantial clinical ben-
efits to BTZ. In patients with1 prior therapy incremental LY, QALY and costs with
LEN/DEX were 1.1 LY (95%CI: 0.4;2.0), 0.8 QALY (95%CI: 0.3;1.5) and 49,266€ (95%CI:
37,730€;67,342€) and in patients with only 1 prior therapy 1.4 LY (95%CI: 0.4;2.9), 1.1
QALY (95%CI: 0.3;2.1) and 57,293€ (95%CI: 39,303€;84,809€), respectively. Corre-
sponding ICERs (LEN/DEX vs BTZ) ranged from 39,770€/LY to 61,649/QALY.
CONCLUSIONS: Lenalidomide plus dexamethasone can be regarded as a cost-ef-
fective choice compared to bortezomib monotherapy for relapsed/refractory mul-
tiple myeloma patients in Portugal.
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OBJECTIVES: Renal cell carcinoma (RCC) is a prevalent form of kidney cancer and is
associated with a poor prognosis. Less than 10% of patients with advanced or
metastatic disease (mRCC) survive beyond 5 years. Recently introduced therapies
are associated with significant clinical improvements over standard treatments
such as interferon alfa (IFN). The objective of this research was to evaluate the
cost-effectiveness of novel first line treatments for mRCC under the Brazilian Pub-
lic Health System perspective.METHODS: A Markov model was designed to simu-
latemRCCprogression,mortality and associated costs. Themodelwas evaluated in
a period of 2 years. A systematic review of the literature was conducted on the
efficacy and safety of pazopanib, sunitinib, and bevacizumab associated to INF in
patients treated for mRCC. Costs and consequences of the disease treatment were
computed for each targeted alternative. Only direct medical costs were considered
and reported in 2011 Brazilian currency (1BRL0.60USD). Costs and outcomeswere
discounted at 5% yearly. Outcomes assessed were progression-free survival (PFS)
and quality adjusted life years (QALY). Stochastic simulations tested model
robustness. RESULTS: No direct comparison studies were found evaluating the
efficacy of the alternatives. Thus, an indirect comparison was applied in order to
determine the relative efficacy of each therapy. The indirect PFS hazzard ratio (95%
CI) suggests that pazopanib is not statistically different from sunitinib (0.93 [0.56,
1.56]) or bevacizumabIFN (0.79 [0.48, 1.32]). Estimated QALYs were 0.93 for
sunitinib, 0.90 for pazopanib, and 0.88 for bevacizumabINF. The incremental
cost-effectiveness ratio (ICER) revealed that sunitinib costs about R$245,000 per
QALY gained compared to pazopanib. BevacizumabINF was dominated across
all scenarios. Sensitivity analysis confirmed the base case results. CONCLUSIONS:
Pazopanib reported lower costs and similar benefits across studied comparators as
first line treatment of patients diagnosed with mRCC under the Brazilian public
perspective.
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OBJECTIVES: To evaluate economics of nilotinib 600 mg and dasatinib 100 mg,
compared to imatinib 400 mg, as first line therapy in chronic myeloid leukemia in
Colombia, from third payer perspective.METHODS: Amarkov model used to eval-
uate 100 patients, aged 55 years, with newly diagnosed CML in chronic phase, in a
10 year time horizon. Progression free life years saved (PF-LYS)were considered the
analysis outcome. Transition probabilitieswere analyzed in themodel according to
literature review. A 3% discount rate was applied to costs and outcomes. In the
absence of any head to head trials to compare nilotinib and dasatinib, comparisons
were made independently for each one versus imatinib. Costs analysis included
direct medical costs obtained from local health care providers databases at prices
for year 2011. Transplantation costs were excluded. Prices for medicines were es-
timated from official government top reimbursement prices. There was a univari-
ate and multivariate Montecarlo sensibility analysis. RESULTS: Nilotinib was
greater expected PF-LYS (15,376 vs. 14,643 for Imatinib), followed by Dasatinib
(15,108 vs. 14,789 for Imatinib). Imatinib had lower total lifetime costs. The incre-
mental cost-effectiveness ratio (ICER) was USD $6.828 per PF-LYS in the Nilotinib
arm and USD $32.501 per PF-LYS for Dasatinib arm, each compared to Imatinib.
When analyzing indirectly Nilotinib vs. Dasatinib, Nilotinib was found to be dom-
inant due to higher efficacy (267,65 PF-LYS) and less costs (USD $5.290) in the base
case. The multivariate sensitivity analysis showed that Nilotinib maintained its
dominance against Imatinib and Dasatinib in most scenarios. The average esti-
mated cost to manage disease progression per three months was USD $ 17.335
which was considered as threshold. CONCLUSIONS: From a third party payer per-
spective in Colombia, using PF-LYS, nilotinib is highly cost-effective when com-
pared to imatinib and dominant vs dasatinib in first line therapy for CML in chronic
phase.
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OBJECTIVES: Patients with non-resectable pancreatic Neuroendocrine Tumors
(NET) have very few therapeutic alternatives. Sunitinib had showed a substantial
clinical benefit in this group of patients, however there are few economic studies
pursuing to estimate its economic consequences. The objective of this studywas to
estimate the cost-effectiveness of sunitinib in the treatment of well-differentiated
non-resectable pancreatic NET, from the perspective of the Social SecurityMexican
Institute (IMSS).METHODS: A three health states Markov model (pre-progression,
post-progression, death; 2-week cycles) was used to estimate the health and eco-
nomic consequences of sunitinib 37.5/day best supportive care (BSC) regarding
placebo BSC along a ten-years horizon (discount rate: 5%). Effectiveness mea-
sures were overall: survival (OS), progression-free survival (PFS) and quality ad-
justed life years gained (QALY). Resource utilization (BSC, adverse events manage-
ment, medical follow up) was estimated through a Delphi Panel with Mexican
oncologists (n10). Unit costs of medication and medical resources were obtained
from institutional sources. Deterministic and probabilistic sensitivity analyses
were developed and acceptability curves were constructed. RESULTS:
SunitinibBSC gained additional 0.49 years of PFS, 1.18 years of OS and 0.70 QALYs
against placeboBSC. SunitinibBSC increasedmedical direct costs (2011 US$) per
patient in $20,854 (around two-fold the cost of placeboBSC: $18,082), which was
driven by acquisition costs of sunitinib and medical follow up before progression
(due to the noted clinical benefit in sunitinib’s patients). ICER’s were $42,157,
$17,662 and $29,808 per progression-free year, life-year and QALY gained, respec-
tively, which remained robust through25% changes inmain parameters. At will-
ingness to pay higher than $40,000, $21,800 and $37,200 sunitinibBSC becomes
the most efficient alternative in regards to PFS, OS and QALYs, respectively.
CONCLUSIONS:At IMSS, sunitinibBSCwould provide substantial clinical benefits
to patients suffering unresectable pancreatic NET, although the latter would in-
crease medical costs of treatment and clinical follow up.
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